CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease The Role of the Pericardium in Heart Failure: Implications for Pathophysiology and Treatment Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors Impact of Intravascular Ultrasound-Guided Drug-Eluting Stent Implantation on Patients With Chronic Kidney Disease: Subgroup Analysis From ULTIMATE Trial Systemic microvascular dysfunction in microvascular and vasospastic angina Sleep quality and risk of coronary heart disease-a prospective cohort study from the English longitudinal study of ageing Atherosclerosis — An Inflammatory Disease Identifying coronary artery disease patients at risk for sudden and/or arrhythmic death: remaining limitations of the electrocardiogram Clinical Risk Factors and Atherosclerotic Plaque Extent to Define Risk for Major Events in Patients Without Obstructive Coronary Artery Disease: The Long-Term Coronary Computed Tomography Angiography CONFIRM Registry Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic Therapy

Original Research

JOURNAL:CBSMD Article Link

Percutaneous Left Atrial Appendage Occlusion: How Much Do We Know?

CBSMD

Pre-reading

  • Definition of percutaneous left artrail appendage occlusion
  • Indications for LAAO therapy

  • How to define study endpoints, stroke and classifications, transient ischemic attack, cardiovascular mortality, non-cardiovascular mortality, procedural mortality, immediate procedural mortality, systemic embolism, pericardial effusion, bleeding events etc.  




RCTs


Year 2009, "Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial"

confirmed the efficacy of percutaneous closure of the LAA with this device was non-inferior to that of warfarin therapy. Although there was a higher rate of adverse safety events in the intervention group than in the control group, events in the intervention group were mainly a result of periprocedural complications. Closure of the LAA might provide an alternative strategy to chronic warfarin therapy for stroke prophylaxis in patients with non-valvular atrial fibrillation.